Review on experimental research of Chinese herbal medicine intervenion for breast cancer

ArticleinZhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 32(18):1947-50 · October 2007with6 Reads
Source: PubMed
  • 21 · Shanghai University of Traditional Chinese Medicine
  • 36.4 · Shanghai University of Traditional Chinese Medicine
A review was about the mechanism of Chinese herbal medicine and its compounds intervening breast cancer in recent years. Experimental results showed that Chinese herbal medicine and its compounds have the activity of anti-cancer, through inhibiting the growth and proliferation of breast cancer cells, restraining the metastasis, appearing the estrogen-like activity and improving multi-drug resistance, and so on.
  • [Show abstract] [Hide abstract] ABSTRACT: Surgery for cancer has made significant progression in recent years and these developments have been in tandem with various adjuvant treatments including chemotherapy and radiotherapy. The concurrent use of traditional Chinese medicine (TCM), a 5,000-year-old art, with surgery has not been popular among those who practice Western style medicine. This is largely due to the different philosophies and relatively lack of scientific evidence of TCM. There is however current intense research on TCM as novel or additional treatment methods for cancer surgery. This chapter reviews the current use of TCM in cancer surgery and the intention is not to coerce the surgeon into using TCM but to increase the awareness of surgeons and provide a stimulus for research. The pathogenesis of cancer according to TCM is discussed. Traditional Chinese medicine has been used successfully during the perioperative period to relieve intestinal obstruction, reduce postoperative ileus and reduce urinary retention after rectal surgery. Traditional Chinese medicine has also been shown to modulate the inflammatory response of surgical stress. Although the reported results of TCM have been exciting thus far, problems of lack of consensus on treatment regimes and questions on the reliability, validity and applicability of published studies prevent its widespread use and these issues will be discussed in this chapter. There is thus a pressing need for surgeons to work with TCM physicians in the continuing research on this area in order to unleash its full potential for our patients.
    Chapter · Aug 2010 · Journal of ethnopharmacology
  • [Show abstract] [Hide abstract] ABSTRACT: Shu-Gan-Liang-Xue Decoction (SGLXD), a traditional Chinese herbal formula used to ameliorate the hot flushes in breast cancer patients, was reported to have anti-tumor effect on breast carcinoma. Estrogen plays a critical role in the genesis and evolution of breast cancer. Aromatase and steroid sulfatase (STS) are key estrogen synthesis enzymes that predominantly contribute to the high local hormone concentrations. The present study was to evaluate the anti-tumor effect of SGLXD on estrogen receptor (ER) positive breast cancer cell line ZR-75-1, and to investigate its underlying mechanisms both in vitro and in vivo. The anti-tumor activity of SGLXD in vitro was investigated using the MTT assay. The in vivo anti-tumor effect of SGLXD was evaluated in non-ovariectomized and ovariectomized athymic nude mice. The effect of SGLXD on enzymatic activity of aromatase and STS was examined using the dual-luciferase reporter (DLR) based on bioluminescent measurements. Aromatase and STS protein level were assessed using Western blot assay. SGLXD showed dose-dependent inhibitory effect on the proliferation of ZR-75-1 cells with IC50 value of 3.40mg/mL. It also suppressed the stimulating effect on cell proliferation of testosterone and estrogen sulfates (E1S). Oral administration of 6g/kg of SGLXD for 25 days resulted in a reduction in tumor volume in non-ovariectomized and ovariectomized nude mice. The bioluminescent measurements confirmed that SGLXD has a dual-inhibitory effect on the activity of aromatase and STS. Western blot assay demonstrated that the treatment of SGLXD resulted in a decrease in aromatase and STS protein levels both in vitro and in vivo. Our results suggested that SGLXD showed anti-tumor effect on breast cancer cells both in vitro and in vivo. The anti-tumor activity of SGLXD is related to inhibition of aromatase and STS via decreasing their expression. SGLXD may be considered as a novel treatment for ER positive breast cancer.
    Article · May 2014
  • undefined · undefined